Edition:
United States

Invion Ltd (IVX.AX)

IVX.AX on Australia Stock Exchange

0.00AUD
12:39am EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.00
Open
$0.00
Day's High
$0.00
Day's Low
$0.00
Volume
5,294,924
Avg. Vol
1,180,339
52-wk High
$0.01
52-wk Low
$0.00

Latest Key Developments (Source: Significant Developments)

Invion Ltd says smoking cessation patent allowance received from China
Wednesday, 9 Mar 2016 08:11pm EST 

Invion Ltd:Smoking cessation patent allowance and operational update.Says notice of allowance received from PR China for use of oral Nadolol in smoking cessation.  Full Article

Invion says Greg Collier has been appointed as interim executive chair of the board
Sunday, 31 Jan 2016 05:08pm EST 

Invion:Says Greg Collier has been appointed as interim executive chair of the board.  Full Article

Invion says joint development and licensing agreement for Zafirlukast
Sunday, 26 Jul 2015 06:42pm EDT 

Invion:Says secured a commitment from hovione scientia limited.Invion to oversee clinical development with first studies expected to begin Q2 2016.Commitment to progress development of inhaled inv104 (zafirlukast) as a potential new treatment for asthma.As consideration for hovione's licensing co will pay an annual royalty to hovione on total net sales of zafirlukast dpi.Hovione to provide expertise on chemistry, particle engineering, formulation, device and gmp manufacturing to develop, manufacture zafirlukast.  Full Article

Invion Ltd announces issue of ordinary shares
Sunday, 26 Apr 2015 09:41pm EDT 

Invion Ltd:Issues 52,458,650 fully paid ordinary shares at an issue price of $0.025 per share.Funds raised will be applied to development of the company's three drug assets as well as for working capital.  Full Article

Invion Ltd announces issue of ordinary shares
Thursday, 23 Apr 2015 08:30pm EDT 

Invion Ltd:Issues 63,213,389 fully paid ordinary shares at an issue price of $0.025 per share.Funds raised will be applied to development of the company's three drug assets as well as for working capital.  Full Article

More From Around the Web

No consensus analysis data available.